Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
12.13
+0.37 (3.10%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Bicara Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Cash & Equivalents
489.71230.444.16
Cash & Short-Term Investments
489.71230.444.16
Cash Growth
112.51%5442.09%-
Receivables
-0.10.07
Prepaid Expenses
12.820.530.76
Total Current Assets
502.53231.074.98
Property, Plant & Equipment
0.850.820.64
Other Long-Term Assets
6.621.990.94
Total Assets
510233.986.7
Accounts Payable
4.513.195.14
Accrued Expenses
12.8811.6118.76
Current Portion of Leases
0.610.29-
Total Current Liabilities
17.9915.0923.9
Long-Term Leases
0.130.37-
Other Long-Term Liabilities
-0.020.09
Total Liabilities
18.1215.4723.98
Common Stock
0.0100
Additional Paid-In Capital
712.884.252.23
Retained Earnings
-221.02-153.02-101.04
Total Common Equity
491.88-148.77-98.8
Shareholders' Equity
491.88218.51-17.28
Total Liabilities & Equity
510233.986.7
Total Debt
0.740.66-
Net Cash (Debt)
488.97229.784.16
Net Cash Growth
112.80%5426.29%-
Net Cash Per Share
29.10396.109.69
Filing Date Shares Outstanding
54.5234.260.43
Total Common Shares Outstanding
54.440.640.43
Working Capital
484.54215.99-18.91
Book Value Per Share
9.04-232.15-230.26
Tangible Book Value
491.88-148.77-98.8
Tangible Book Value Per Share
9.04-232.15-230.26
Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q